The rare, inherited neurodegenerative disorder Huntington's Disease (HD) has no known cure. But research from the Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium published last week in Cell reveals promising genetic targets for therapeutic development. Identified by genome-wide association, variants of these genes modify the age of neurologic onset of HD, supporting the notion that HD pathogenesis can be influenced prior to the appearance of clinical disease. The GeM-HD Consortium includes Broad Institute researchers Jim Gusella, Marcy MacDonald, and Jong-Min Lee of the Broad’s Medical and Population Genetics Program, who worked with the Broad Genomics Platform to generate data for this study.
News-in-brief / 08.3.15